Monthly information on share capital and company voting rights
10 Mai 2022 - 10:43PM
Monthly information on share capital and company voting rights
Listing market: Euronext GrowthISIN code: FR0010425595
Date |
Total number of shares in the
capital |
Total number of voting rights |
04/30/2022 |
45,510,810 |
51,103,431 |
About Cellectis Cellectis
is a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 22 years of expertise in gene
editing, Cellectis is developing life-changing product candidates
utilizing TALEN®, its gene editing technology, and PulseAgile, its
pioneering electroporation system to harness the power of the
immune system in order to treat diseases with unmet medical
needs. As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing lifesaving UCART product
candidates for multiple cancers including acute myeloid leukemia
(AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple
myeloma (MM). HEAL is a new platform focusing on hemopoietic stem
cells to treat blood disorders, immunodeficiencies
and lysosomal storage diseases. Cellectis’ headquarters are
in Paris, France, with locations in New York, New York and Raleigh,
North Carolina. Cellectis is listed on the Nasdaq Global Market
(ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
AlloCAR T™ is a trademark of Allogene
Therapeutics, Inc.
For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn
and YouTube.
For further information, please
contact: Media
contacts: Pascalyne
Wilson, Director, Communications, +33776991433,
media@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation contact: Arthur Stril,
Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci Advisors,
+1 (617) 430 7577
Forward-looking
Statements This press release contains
“forward-looking” statements within the meaning of applicable
securities laws, including the Private Securities Litigation Reform
Act of 1995. Forward-looking statements may be identified by words
such as “anticipate,” “believe,” “intend”, “expect,” “plan,”
“scheduled,” “could” and “will,” or the negative of these and
similar expressions. These forward-looking statements, which are
based on our management’s current expectations and assumptions and
on information currently available to management, including
information provided or otherwise publicly reported by our licensed
partners. Forward-looking statements include statements about
advancement, timing and progress of clinical trials (including
with respect to patient enrollment and follow-up), the timing of
our presentation of data and submission of regulatory filngs, the
operational capabilities at our manufacturing facilities, the
potential of our preclinical programs, and the sufficiency of cash
to fund operations. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development as well as the duration and severity of the COVID-19
pandemic and governmental and regulatory measures implemented in
response to the evolving situation. With respect to our cash
runway, our operating plans, including product development plans,
may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2021 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- Voting_Rights_PR_April_EN_docx
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024